Form 4 for ABBV AbbVie
Accepted 2025-02-18 00:00:00 ET · period of report 2025-02-13 · accession 0001415889-25-004457 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-18 | 2025-02-13 | ABBV | Donoghoe Nicholas | EVP, CHIEF BUS, STRAT Off | A - Grant | $0.00 | +25.3K | 71.4K | +55% | $0 |
| D | 2025-02-18 | 2025-02-13 | ABBV | Donoghoe Nicholas | EVP, CHIEF BUS, STRAT Off | A - Grant | $0.00 | +23.4K | 23.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2025-02-13 | A | A | 11,017 | $0.00 | 66,920 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| 2 | Common | Common Stock, $0.01 par value | 2025-02-13 | A | A | 5,174 | $0.00 | 81,248 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| 3 | Common | Common Stock, $0.01 par value | 2025-02-13 | A | A | 4,634 | $0.00 | 76,074 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| 4 | Common | Common Stock, $0.01 par value | 2025-02-13 | A | A | 4,520 | $0.00 | 71,440 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| 5 | Derivative | Option (Right to buy) | 2025-02-13 | A | A | 23,437 | $0.00 | 23,437 | D | $192.86 · — to 2035-02-12 | 23,437 Common Stock | (F5) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028. |